Pioglitazone Teva

RSS
Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 31 March 2023, the European Commission withdrew the marketing authorisation for Pioglitazone Teva (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Pioglitazone Teva was granted marketing authorisation in the EU on 26 March 2012 for the treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity on 17 February 2017. 

Pioglitazone Teva is a generic medicine of Actos, which is authorised and marketed in the EU to treat type 2 diabetes mellitus. 

The European Public Assessment Report (EPAR) for Pioglitazone Teva is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (806.53 KB - PDF)

View

español (ES) (698.1 KB - PDF)

View

čeština (CS) (775.18 KB - PDF)

View

dansk (DA) (638.91 KB - PDF)

View

Deutsch (DE) (698.57 KB - PDF)

View

eesti keel (ET) (698.03 KB - PDF)

View

ελληνικά (EL) (813.13 KB - PDF)

View

français (FR) (700.69 KB - PDF)

View

italiano (IT) (714.74 KB - PDF)

View

latviešu valoda (LV) (748.61 KB - PDF)

View

lietuvių kalba (LT) (663.55 KB - PDF)

View

magyar (HU) (707.11 KB - PDF)

View

Malti (MT) (773.35 KB - PDF)

View

Nederlands (NL) (698.64 KB - PDF)

View

polski (PL) (774.44 KB - PDF)

View

português (PT) (696.95 KB - PDF)

View

română (RO) (664.63 KB - PDF)

View

slovenčina (SK) (770.33 KB - PDF)

View

slovenščina (SL) (767.4 KB - PDF)

View

Suomi (FI) (698.83 KB - PDF)

View

svenska (SV) (696.94 KB - PDF)

View

Product information

български (BG) (2.02 MB - PDF)

View

español (ES) (1.1 MB - PDF)

View

čeština (CS) (1.78 MB - PDF)

View

dansk (DA) (1.11 MB - PDF)

View

Deutsch (DE) (1.18 MB - PDF)

View

eesti keel (ET) (1.11 MB - PDF)

View

ελληνικά (EL) (2.12 MB - PDF)

View

français (FR) (1.14 MB - PDF)

View

hrvatski (HR) (1.16 MB - PDF)

View

íslenska (IS) (1.11 MB - PDF)

View

italiano (IT) (1.13 MB - PDF)

View

latviešu valoda (LV) (1.79 MB - PDF)

View

lietuvių kalba (LT) (1.15 MB - PDF)

View

magyar (HU) (1.74 MB - PDF)

View

Malti (MT) (1.85 MB - PDF)

View

Nederlands (NL) (1.12 MB - PDF)

View

norsk (NO) (1.13 MB - PDF)

View

polski (PL) (1.82 MB - PDF)

View

português (PT) (1.13 MB - PDF)

View

română (RO) (1.22 MB - PDF)

View

slovenčina (SK) (1.79 MB - PDF)

View

slovenščina (SL) (1.73 MB - PDF)

View

Suomi (FI) (1.13 MB - PDF)

View

svenska (SV) (1.12 MB - PDF)

View
Latest procedure affecting product information: N/0025
04/11/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (647.96 KB - PDF)

View

español (ES) (597.6 KB - PDF)

View

čeština (CS) (623.96 KB - PDF)

View

dansk (DA) (598.33 KB - PDF)

View

Deutsch (DE) (596.47 KB - PDF)

View

eesti keel (ET) (600.83 KB - PDF)

View

ελληνικά (EL) (651.29 KB - PDF)

View

français (FR) (594.42 KB - PDF)

View

íslenska (IS) (593.28 KB - PDF)

View

italiano (IT) (595.34 KB - PDF)

View

latviešu valoda (LV) (639.69 KB - PDF)

View

lietuvių kalba (LT) (625.13 KB - PDF)

View

magyar (HU) (640.79 KB - PDF)

View

Malti (MT) (638.55 KB - PDF)

View

Nederlands (NL) (599.85 KB - PDF)

View

norsk (NO) (596.61 KB - PDF)

View

polski (PL) (623.95 KB - PDF)

View

português (PT) (595.51 KB - PDF)

View

română (RO) (623.32 KB - PDF)

View

slovenčina (SK) (638.75 KB - PDF)

View

slovenščina (SL) (610.12 KB - PDF)

View

Suomi (FI) (595.16 KB - PDF)

View

svenska (SV) (595.08 KB - PDF)

View

български (BG) (702.36 KB - PDF)

View

español (ES) (603.16 KB - PDF)

View

čeština (CS) (701.28 KB - PDF)

View

dansk (DA) (597.36 KB - PDF)

View

Deutsch (DE) (604.17 KB - PDF)

View

eesti keel (ET) (602.64 KB - PDF)

View

ελληνικά (EL) (700.03 KB - PDF)

View

français (FR) (603.69 KB - PDF)

View

íslenska (IS) (603.62 KB - PDF)

View

italiano (IT) (602.8 KB - PDF)

View

latviešu valoda (LV) (704.74 KB - PDF)

View

lietuvių kalba (LT) (670.52 KB - PDF)

View

magyar (HU) (667.73 KB - PDF)

View

Malti (MT) (702.84 KB - PDF)

View

norsk (NO) (603.22 KB - PDF)

View

polski (PL) (702.45 KB - PDF)

View

português (PT) (598.07 KB - PDF)

View

română (RO) (667.78 KB - PDF)

View

slovenčina (SK) (693.87 KB - PDF)

View

slovenščina (SL) (692.99 KB - PDF)

View

Suomi (FI) (597.87 KB - PDF)

View

svenska (SV) (603.53 KB - PDF)

View

Product details

Name of medicine
Pioglitazone Teva
Active substance
pioglitazone hydrochloride
International non-proprietary name (INN) or common name
pioglitazone
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BG03

Pharmacotherapeutic group

Alimentary tract and metabolism

Therapeutic indication

Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:

  • as monotherapy
    - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
  • as dual oral therapy in combination with
    - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin
    - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea
  • as triple oral therapy in combination with
    - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Authorisation details

EMA product number
EMEA/H/C/002297

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Teva B.V.

Swensweg 5
2031GA Haarlem
The Netherlands

Opinion adopted
19/01/2012
Marketing authorisation issued
26/03/2012
Revision
12

Assessment history

This page was last updated on

Share this page